"Pyridazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
| Descriptor ID |
D011724
|
| MeSH Number(s) |
D03.383.710
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridazines".
Below are MeSH descriptors whose meaning is more specific than "Pyridazines".
This graph shows the total number of publications written about "Pyridazines" by people in this website by year, and whether "Pyridazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 2 | 5 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 4 | 1 | 5 |
| 2015 | 4 | 1 | 5 |
| 2016 | 3 | 2 | 5 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 3 | 4 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridazines" by people in Profiles.
-
Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo. Oncotarget. 2017 Jan 24; 8(4):5874-5884.
-
The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. Invest New Drugs. 2016 12; 34(6):685-692.
-
Chronic Unpredictable Mild Stress Induces Loss of GABA Inhibition in Corticotrophin-Releasing Hormone-Expressing Neurons through NKCC1 Upregulation. Neuroendocrinology. 2017; 104(2):194-208.
-
Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib. Pediatr Blood Cancer. 2015 Nov; 62(11):2050-1.
-
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73.
-
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther. 2014 Oct; 13(10):2315-27.
-
The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs. 2014 Oct; 32(5):815-24.
-
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Jul; 23(7):943-54.
-
Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S317-29.
-
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1599-607.